Examiner Cite

No

Initial*

Patent Number

Remove

Remove

Figures Appear

Pages,Columns,Lines where

Relevant Passages or Relevant

	Application Number	10561541		
	Filing Date		2005-12-19	
INFORMATION DISCLOSURE	First Named Inventor Barzi		lay, Amir	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1612	
(Not for Submission and or or or it issue	Examiner Name	Snigd	ha Maewall	

Code¹ Issue Date

	Filing Date		2005-12-19	
IFORMATION DISCLOSURE	First Named Inventor Barzi		zilay, Amir	
TATEMENT BY APPLICANT lot for submission under 37 CFR 1.99)	Art Unit		1612	
iot for submission under 57 of it 1.55)	Examiner Name Snigdha Maewall		ha Maewall	
	Attorney Docket Numb	er	15872.091	

U.S. PATENTS

Name of Patentee or Applicant

of cited Document

	1							
If you wisl	If you wish to add additional U.S. Patent citation information please click the Add button. Add							
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button. Add								

If you wish to add additional U.S. Published Application citation information please click the Add button. Add							
		FORE	GN PAT	ENT DOCUM	ENTS	Remove	
Cite No	Foreign Document Number ³	Country Code ² j	Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	тя
1	10-155428	JP		1998-06-16	ITO, YOSHINORI	English translation of Abstract only	×
2	11-009196	JP		1999-01-19	SHIRAISHI, OSAMU	English translation of Abstract only	×
	Cite No	Cite Foreign Document Number ³ 1 10-155428	Cite Foreign Document Country Code2 i 1 10-155428 JP	FOREIGN PAT Citle Foreign Document Country Kind No Number ³ Code ² i Code ⁴ 1 10-155429 JP	FOREIGN PATENT DOCUM Cite	Cite Foreign Document Country Code ²	POREION PATENT DOCUMENTS Remove

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published	Тs	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at were LISETIC GOU're MEPE 901.6.2 Electe office that issued the document, by the Novelter code (WIPO Standard ST3.) 3 For Juspanes patent colourests, but includes on the year of the Emperor many percedule see seel number of the patent document, but included colourests, but included not they are office office office office of the Emperor many percedule seels number of the patent document, and for the seel of the Emperor many percedule seels number of the patent document.

**Include office office of the Emperor Many percedules of the Empero

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10561541	
Filing Date		2005-12-19	
First Named Inventor	Barzilay, Amir		
Art Unit		1612	
Examiner Name	Snigdha Maewall		
Attorney Docket Number		15872 091	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

Rodney J. Fuller

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.	nature.					
Signature	/Rodney J. Fuller/	Date (YYYY-MM-DD)	2011-11-23			

Registration Number

46714

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is of lie (and by the USPTO by process) an application. Confidentiality is governed by \$5.1.8.C. 12.0 and 37 CFR.
1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sort to the Chief Information Officer, U.S. Partent and Trademark Office. U.S. Department of Commerce, P.O. Box 1459, Alexandria, VA 2231-31450. DO NOT SEND FEES OF COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1459, Alexandria, Va 2211-3169.

Name/Print

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.